Intraperitoneal chemotherapy in the management of malignant disease

References

• Dedrick RL, Myers CE, Bungay PM et al.Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat. Rep. 62,1–9 (1978).
   PubMedGoogle Scholar
• ••Paper renewed interest in the theoreticalbenefits associated with regional therapy of ovarian cancer.
   Google Scholar
• Dedrick RL. Theoretical and experimental bases of intraperitoneal chemotherapy. Semin. Oncol. 12(3, Suppl. 4), 1–6 (1985).
   Google Scholar
• Alberts DS, Young L, Mason N et al. hi vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Semin. Oncol 12(3, Suppl. 4), 38–42 (1985).
   Google Scholar
• Weisberger AS, Levine B, Storaasli JR Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. J. Am. Med. Assoc. 159,1704–1707 (1955).
   PubMed Web of Science ®Google Scholar
• Markman M. Intraperitoneal therapy for treatment of malignant disease principally confined to the peritoneal cavity. Ctit. Rev OncoHlematol 14,15–28 (1993).
   PubMed Web of Science ®Google Scholar
• Howell SB, Pfeifle CE, Wung WE et al Intraperitoneal cisplatin with systemic thiosulfate protection. Ann. Intern. Med. 97,845–851 (1982).
   PubMed Web of Science ®Google Scholar
• Casper ES, Kelsen DP, Alcock NW et al. Ip. cisplatin in patients with malignant ascites: pharmacokinetics evaluation and comparison with the iv. route. Cancer Peat. Rep. 67,325-338 (1983).
   Google Scholar
• Lopez JA, Krikorian JG, Reich SD et al. Clinical pharmacology of intraperitonealcisplatin. Cynecol Oncol 20,1–9 (1985).
   PubMed Web of Science ®Google Scholar
• Pretorius RG, Hacker NF, Berek JS et al. Pharmacokinetics of Ip. cisplatin in refractory ovarian carcinoma. Cancer Treat. Rep. 67,1085–1092 (1983).
   PubMedGoogle Scholar
• Elferink F, van der Vijgh WJF, Klein I, ten Bokkel Huinink WW, Dubbelman R, McVie JG. Pharmacokinetics of carboplatin after intraperitoneal administration. Cancer Chemother. Pharmacol. 21, 57–60 (1988)
   PubMed Web of Science ®Google Scholar
• DeGregorio MW, Lum BL Holleran WM, Wilbur BJ, Sikic BI. Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a Phase I study of the Northern California Oncology Group. Cancer Chemother. Pharmacol. 18,235–238 (1986).
   PubMed Web of Science ®Google Scholar
• Demicheli R, Jirillo A, Bonciarelli G et al. Pharmacological data and technical feasibility of intraperitoneal 5—fluorouracil administration. Tumori 68,437–441 (1982).
   PubMedGoogle Scholar
• Speyer JL, Collins JM, Dedrick RL et al. Phase land pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res. 40,567–572 (1980).
   PubMed Web of Science ®Google Scholar
• Speyer JL, Sugarbaker PH, Collins JM, Dedrick RL, Klecker RVV, Jr., Myers CE. Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res. 41, 1916–1922 (1981).
   Google Scholar
• Markman M, Rowinsky E, Hakes T et al. Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group Study. Clin. Oncol. 10,1485–1491 (1992).
   Google Scholar
• •Paper demonstrated the major pharmacokinetics advantage associated with regional delivery of paclitaxel.
   Google Scholar
• Francis P, Rowinsky E, Schneider J et al. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study. Clin. 0=113, 2961–2967 (1995).
   Google Scholar
• Markman M. Intraperitoneal therapy of ovarian cancer. Semin. Oncol 25, 356–360 (1998).
   PubMed Web of Science ®Google Scholar
• Markman M, Reichman B, Hakes T et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. j Clin. Oncol 9,1801–1805 (1991).
   PubMed Web of Science ®Google Scholar
• •Paper demonstrated the importance of both size of residual disease and documented chemosensitivity in determining clinical utility of ip. cisplatin.
   Google Scholar
• Markman M, Berek JS, Blessing JA et al. Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based IP chemotherapy: lessons learned from a Gynecologic Oncology Group Phase II trial of IP cisplatin and recombinant a-interferon. Cynecol Oncol 45,3–8 (1992).
   PubMed Web of Science ®Google Scholar
• Markman M, Blessing JA, Major F et al. Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: a Gynecologic Oncology Group Study. Cynecol Oncol 50,191–195 (1993).
   PubMed Web of Science ®Google Scholar
• West GW, Weichselbau R, Little JB. Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance
   Google Scholar
• •• to adjuvant chemotherapy. Cancer Res. 40, 3665–3668 (1980).
   Google Scholar
• Nederman T, Carlsson J. Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids. Cancer Chemother. Pharmacol 13, 131–135 (1984).
   Google Scholar
• Durand RE. Flow cytometry studies of intracellular adriamycin in multicell spheroids in vitm. Cancer Res. 41, 3495–3498 (1981).
   PubMed Web of Science ®Google Scholar
• Ozols RF, Locker GY, Doroshow JH et al. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res. 39, 3209–3214 (1979).
   PubMed Web of Science ®Google Scholar
• Los G, Mutsaers PHA, van der Vijgh WJF et al Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res. 49, 3380–3384 (1989).
   PubMed Web of Science ®Google Scholar
• Markman M, Brady MF, Spirtos NM etal. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary tube and peritoneum: a Gynecologic Oncology Group Study. Clin. Oncol 16, 2620–2624 (1998).
   Google Scholar
• Kasen DP, Saltz L, Cohen AM et al. A Phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high-risk colon cancer. Cancer74, 2224–2233 (1994).
   PubMedGoogle Scholar
• Atiq OT, Kasen DP, Shiu MET et al. Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer. j Clin. Oncol 11, 425–433 (1993).
   PubMed Web of Science ®Google Scholar
• Leichman L, Silberman H, Leichman CG et al. Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: A University of Southern California Pilot Program.j Clin. Oncol 10, 1933–1942 (1992).
   PubMed Web of Science ®Google Scholar
• Kasen D, Karpeh M, Schwartz G et al. Neoadjuvant therapy of high-risk gastric cancer: A Phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. I Clin. 0=1 14, 1818–1828 (1996).
   Google Scholar
• Howell SB, Zimm S, Markman M et al. Long-term survival of advanced refractory ovarian carcinoma patients with small- volume disease treated with intraperitoneal chemotherapy. j Clin. Oncol 5, 1607–1612 (1987).
   PubMed Web of Science ®Google Scholar
• Markman M, Reichman B, Hakes T et al. Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer. j Clin. Oncol 10, 1479–1484 (1992).
   PubMed Web of Science ®Google Scholar
• Recio FO, Piver MS, Hempling RE, Driscoll DL. Five-year survival after second-line cisplatin-based intraperitoneal chemotherapy for advanced ovarian cancer. Cynecol Oncol 68, 267–273 (1998).
   PubMedGoogle Scholar
• Sugarbaker PH, Zhu B-W, Banez Sese G, Shmookler B. Peritoneal carcinomatosis from appendiceal cancer: Results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy. Dis. Colon Rectum36, 323–329 (1993).
   Google Scholar
• Sugarbaker PH, Jablonski IKA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann. Surg. 132, 124–132 (1995).
   Google Scholar
• Antman KH, Klegar KL, Pomfret EA etal. Early peritoneal mesothelioma. A treatable malignancy. Lancet 2, 977–980 (1985).
   Google Scholar
• Lederman GS, Recht A, Herman T Long- term survival in peritoneal mesothelioma: the role of radiotherapy and combined modality treatment. Cancer59, 1882–1886 (1987).
   PubMedGoogle Scholar
• Alberts DS, Liu PY, Hannigan EV et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide vermsintravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. Merl 335, 1950–1955 (1996). Paper documented the survival advantage associated with regional delivery of cisplatin when employed as initial therapy of small volume advanced ovarian cancer.
   Google Scholar
• Markman M, Bundy BN, Alberts DS etal. Phase III trial of standard dose intravenous cisplatin plus paclitaxel versusmoderately high dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group and Eastern Cooperative Oncology Group. J. Clin. Oncol 19, 1001–1007 (2001).
   Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351, 1451–1467 (1998).
   PubMed Web of Science ®Google Scholar
• McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl. I Merl 334, 1–6 (1996).
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Gianola FJ, Speyer JC, Wesley R, Barofsky I, Meyers CE. Prospective, randomized trial of intravenous versusintraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surgety98, 414–421 (1985).
   PubMed Web of Science ®Google Scholar
• Hagiwara A, Takahashi T, Kojima 0 et al. Prophylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet339, 629–631 (1992).
   Google Scholar
• Rosen HR, Jatzko G, Repse S et al. Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: Results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. J. Clin. Oncol 16, 2733–2738 (1998).
   PubMedGoogle Scholar
• Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer85, 529–534 (1999).
   PubMed Web of Science ®Google Scholar
• Yu W, Whang I, Suh I, Averbach A, Chang D, Sugarbaker PH. Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann. Surg. 228, 347–354 (1998).
   PubMed Web of Science ®Google Scholar
• Valliant J-C, Nordlinger B, Deuffic S et al. Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer. Ann. Surg. 231, 449–456 (2000).
   Google Scholar
• Yu W Whang I, Averbach A, Chang D, Sugarbaker PH. Morbidity and mortality of early postoperative intraperitoneal chemotherapy as adjuvant therapy for gastric cancer. Am. Sing. 64, 1104–1108 (1998).
   Google Scholar
• Pfeiffer P, Bennedbaek O, Bertelsen K. Intraperitoneal carboplatin in the treatment of minimal residual ovarian cancer. Cynecol 0=1 36, 306–311 (1990).
   Google Scholar
• Speyer JL, Beller U, Colombo N et al. Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy. Clin. Oncol 8, 1335–1341 (1990).
   Google Scholar